<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00555412</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-004-102</org_study_id>
    <nct_id>NCT00555412</nct_id>
  </id_info>
  <brief_title>Staccato Loxapine Multidose PK</brief_title>
  <official_title>Safety, Tolerability, and Pharmacokinetics of Multiple Doses of StaccatoÂ® Loxapine for Inhalation in Subjects on Chronic, Stable Antipsychotic Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atlanta Center for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this trial are to assess the safety, tolerability, and pharmacokinetics of
      multiple inhaled doses of Staccato Loxapine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the present Phase 1 study in schizophrenic patients is to assess the safety
      and pharmacokinetics of multiple doses of Staccato Loxapine given within a 24 hour time
      period. The study will be conducted in schizophrenic patients who are on chronic, stable
      antipsychotic medication. Patients meeting entry criteria will be randomized to one of three
      dose sequences of Staccato Loxapine or to Staccato Placebo. Following administration of
      medications, safety, tolerability and pharmacokinetic assessments will be conducted at serial
      time points.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters: tmax, Cmax, AUClast, AUCinf, ke, t1/2 and clearance will be estimated for each subject and for the population using noncompartmental methods.</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration-time (PK) profiles will be produced for each subject and a mean PK profile for subjects completing for each dose group</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability will be assessed based on treatment emergent adverse events, vital signs, ECG and a visual-analog sedation scale.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Volunteers on Chronic, Stable Antipsychotic Regimens</condition>
  <arm_group>
    <arm_group_label>A - 10 mg loxapine q 4 h x 3 (30 mg total)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C - 5 mg loxapine q 4 h x 3 (15 mg total)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D - inhaled placebo q 4 h x 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A - 10 mg loxapine q 4 h x 3 (30 mg total)</intervention_name>
    <description>loxapine aerosol inhalation high dose regimen (30 mg total)</description>
    <arm_group_label>A - 10 mg loxapine q 4 h x 3 (30 mg total)</arm_group_label>
    <other_name>Staccato Loxapine 10 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)</intervention_name>
    <description>loxapine aerosol inhalation middle dose regimen (20 mg total)</description>
    <arm_group_label>B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)</arm_group_label>
    <other_name>Staccato Loxapine 5 and 10 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C - 5 mg loxapine q 4 h x 3 (15 mg total)</intervention_name>
    <description>loxapine aerosol inhalation low dose regimen (15 mg total)</description>
    <arm_group_label>C - 5 mg loxapine q 4 h x 3 (15 mg total)</arm_group_label>
    <other_name>Staccato Loxapine 5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D - inhaled placebo q 4 h x 3</intervention_name>
    <description>placebo aerosol inhalation (0 mg total)</description>
    <arm_group_label>D - inhaled placebo q 4 h x 3</arm_group_label>
    <other_name>Staccato Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:

          1. Male and female subjects between the ages of 18 to 65 years, inclusive.

          2. Subjects who are on stable, oral, chronic (&gt;2 mos) antipsychotic medication regimen
             and who are able to tolerate the rapid oral dose taper and substitution regimen.

        Exclusion Criteria include:

          1. Subjects who are currently treated with injectable depot neuroleptics within one dose
             interval must be excluded.

          2. Subjects who have received loxapine or amoxapine within the last 30 days must be
             excluded.

          3. Subjects with a history of allergy or intolerance to dibenzoxazepines (loxapine and
             amoxapine) must be excluded.

          4. Subjects with a history of movement disorders including Parkinson's disease or a
             history of neuroleptic malignant syndrome must be excluded.

          5. Subjects who have a history within the past year of drug or alcohol dependence or
             abuse as defined by DSM-4 must be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Riesenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlanta Center for Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Spyker DA, Riesenberg RA, Cassella JV. Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens. J Clin Pharmacol. 2015 Sep;55(9):985-94. doi: 10.1002/jcph.502. Epub 2015 May 6.</citation>
    <PMID>25808074</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2007</study_first_submitted>
  <study_first_submitted_qc>November 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2007</study_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetic</keyword>
  <keyword>multidose</keyword>
  <keyword>Staccato Loxapine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loxapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

